1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 1103 pages

Inflammation - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Inflammation - Pipeline Review, H1 2014’, provides an overview of the Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Inflammation - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
Introduction 11
Inflammation Overview 12
Therapeutics Development 13
Inflammation - Therapeutics under Development by Companies 15
Inflammation - Therapeutics under Investigation by Universities/Institutes 35
Inflammation - Pipeline Products Glance 41
Inflammation - Products under Development by Companies 45
Inflammation - Products under Investigation by Universities/Institutes 75
Inflammation - Companies Involved in Therapeutics Development 82
Inflammation - Therapeutics Assessment 304
Drug Profiles 333
Inflammation - Recent Pipeline Updates 959
Inflammation - Dormant Projects 1002
Inflammation - Discontinued Products 1033
Inflammation - Product Development Milestones 1036
Appendix 1043

List of Tables

Number of Products under Development for Inflammation, H1 2014 72
Number of Products under Development for Inflammation - Comparative Analysis, H1 2014 73
Number of Products under Development by Companies, H1 2014 75
Number of Products under Development by Companies, H1 2014 (Contd..1) 76
Number of Products under Development by Companies, H1 2014 (Contd..2) 77
Number of Products under Development by Companies, H1 2014 (Contd..3) 78
Number of Products under Development by Companies, H1 2014 (Contd..4) 79
Number of Products under Development by Companies, H1 2014 (Contd..5) 80
Number of Products under Development by Companies, H1 2014 (Contd..6) 81
Number of Products under Development by Companies, H1 2014 (Contd..7) 82
Number of Products under Development by Companies, H1 2014 (Contd..8) 83
Number of Products under Development by Companies, H1 2014 (Contd..9) 84
Number of Products under Development by Companies, H1 2014 (Contd..10) 85
Number of Products under Development by Companies, H1 2014 (Contd..11) 86
Number of Products under Development by Companies, H1 2014 (Contd..12) 87
Number of Products under Development by Companies, H1 2014 (Contd..13) 88
Number of Products under Development by Companies, H1 2014 (Contd..14) 89
Number of Products under Development by Companies, H1 2014 (Contd..15) 90
Number of Products under Development by Companies, H1 2014 (Contd..16) 91
Number of Products under Development by Companies, H1 2014 (Contd..17) 92
Number of Products under Development by Companies, H1 2014 (Contd..18) 93
Number of Products under Investigation by Universities/Institutes, H1 2014 95
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 98
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 99
Comparative Analysis by Late Stage Development, H1 2014 100
Comparative Analysis by Clinical Stage Development, H1 2014 101
Comparative Analysis by Early Stage Development, H1 2014 102
Comparative Analysis by Unknown Stage Development, H1 2014 103
Products under Development by Companies, H1 2014 104
Products under Development by Companies, H1 2014 (Contd..1) 105
Products under Development by Companies, H1 2014 (Contd..2) 106
Products under Development by Companies, H1 2014 (Contd..3) 107
Products under Development by Companies, H1 2014 (Contd..4) 108
Products under Development by Companies, H1 2014 (Contd..5) 109
Products under Development by Companies, H1 2014 (Contd..6) 110
Products under Development by Companies, H1 2014 (Contd..7) 111
Products under Development by Companies, H1 2014 (Contd..8) 112
Products under Development by Companies, H1 2014 (Contd..9) 113
Products under Development by Companies, H1 2014 (Contd..10) 114
Products under Development by Companies, H1 2014 (Contd..11) 115
Products under Development by Companies, H1 2014 (Contd..12) 116
Products under Development by Companies, H1 2014 (Contd..13) 117
Products under Development by Companies, H1 2014 (Contd..14) 118
Products under Development by Companies, H1 2014 (Contd..15) 119
Products under Development by Companies, H1 2014 (Contd..16) 120
Products under Development by Companies, H1 2014 (Contd..17) 121
Products under Development by Companies, H1 2014 (Contd..18) 122
Products under Development by Companies, H1 2014 (Contd..19) 123
Products under Development by Companies, H1 2014 (Contd..20) 124
Products under Development by Companies, H1 2014 (Contd..21) 125
Products under Development by Companies, H1 2014 (Contd..22) 126
Products under Development by Companies, H1 2014 (Contd..23) 127
Products under Development by Companies, H1 2014 (Contd..24) 128
Products under Development by Companies, H1 2014 (Contd..25) 129
Products under Development by Companies, H1 2014 (Contd..26) 130
Products under Development by Companies, H1 2014 (Contd..27) 131
Products under Development by Companies, H1 2014 (Contd..28) 132
Products under Development by Companies, H1 2014 (Contd..29) 133
Products under Investigation by Universities/Institutes, H1 2014 134
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 135
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 136
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 137
Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 138
Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 139
Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 140
Inflammation - Pipeline by Bristol-Myers Squibb Company, H1 2014 141
Inflammation - Pipeline by Johnson and Johnson, H1 2014 142
Inflammation - Pipeline by Boehringer Ingelheim GmbH, H1 2014 143
Inflammation - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 144
Inflammation - Pipeline by Amgen Inc., H1 2014 145
Inflammation - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 146
Inflammation - Pipeline by GlaxoSmithKline plc, H1 2014 147
Inflammation - Pipeline by Genentech, Inc., H1 2014 148
Inflammation - Pipeline by Nektar Therapeutics, H1 2014 149
Inflammation - Pipeline by Agenus, Inc., H1 2014 150
Inflammation - Pipeline by MedImmune, LLC, H1 2014 151
Inflammation - Pipeline by Gilead Sciences, Inc., H1 2014 152
Inflammation - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 153
Inflammation - Pipeline by Merck and Co., Inc., H1 2014 154
Inflammation - Pipeline by Ablynx NV, H1 2014 155
Inflammation - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 156
Inflammation - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 157
Inflammation - Pipeline by Euroscreen S.A., H1 2014 158
Inflammation - Pipeline by Novo Nordisk A/S, H1 2014 159
Inflammation - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 160
Inflammation - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 161
Inflammation - Pipeline by Piramal Enterprises Limited, H1 2014 162
Inflammation - Pipeline by Amorepacific Corporation, H1 2014 163
Inflammation - Pipeline by Astellas Pharma Inc., H1 2014 164
Inflammation - Pipeline by Kowa Company, Ltd., H1 2014 165
Inflammation - Pipeline by LEO Pharma A/S, H1 2014 166
Inflammation - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 167
Inflammation - Pipeline by Pfizer Inc., H1 2014 168
Inflammation - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 169
Inflammation - Pipeline by UCB S.A., H1 2014 170
Inflammation - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 171
Inflammation - Pipeline by Exelixis, Inc., H1 2014 172
Inflammation - Pipeline by Celgene Corporation, H1 2014 173
Inflammation - Pipeline by Bayer AG, H1 2014 174
Inflammation - Pipeline by Incyte Corporation, H1 2014 175
Inflammation - Pipeline by Merck KGaA, H1 2014 176
Inflammation - Pipeline by Evotec AG, H1 2014 177
Inflammation - Pipeline by Harbor Therapeutics, Inc., H1 2014 178
Inflammation - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 179
Inflammation - Pipeline by Star Scientific, Inc., H1 2014 180
Inflammation - Pipeline by Genfit SA, H1 2014 181
Inflammation - Pipeline by Can-Fite BioPharma Ltd., H1 2014 182
Inflammation - Pipeline by Karo Bio AB, H1 2014 183
Inflammation - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 184
Inflammation - Pipeline by TG Therapeutics, Inc., H1 2014 185
Inflammation - Pipeline by Lpath, Inc., H1 2014 186
Inflammation - Pipeline by Lupin Limited, H1 2014 187
Inflammation - Pipeline by Basilea Pharmaceutica AG, H1 2014 188
Inflammation - Pipeline by NicOx S.A., H1 2014 189
Inflammation - Pipeline by Compugen Ltd., H1 2014 190
Inflammation - Pipeline by Orchid Chemicals and Pharmaceuticals Ltd, H1 2014 191
Inflammation - Pipeline by Palatin Technologies, Inc., H1 2014 192
Inflammation - Pipeline by Pharmaxis Limited, H1 2014 193
Inflammation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2014 194
Inflammation - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 195
Inflammation - Pipeline by CSL Limited, H1 2014 196
Inflammation - Pipeline by Cytomedix, Inc., H1 2014 197
Inflammation - Pipeline by Array BioPharma Inc., H1 2014 198
Inflammation - Pipeline by Dynavax Technologies Corporation, H1 2014 199
Inflammation - Pipeline by XOMA Corporation, H1 2014 200
Inflammation - Pipeline by MorphoSys AG, H1 2014 201
Inflammation - Pipeline by BioInvent International AB, H1 2014 202
Inflammation - Pipeline by Transgene SA, H1 2014 203
Inflammation - Pipeline by Progen Pharmaceuticals Limited, H1 2014 204
Inflammation - Pipeline by JW Pharmaceutical Corporation, H1 2014 205
Inflammation - Pipeline by Galectin Therapeutics, Inc., H1 2014 206
Inflammation - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 207
Inflammation - Pipeline by Biotie Therapies Corp., H1 2014 208
Inflammation - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014 209
Inflammation - Pipeline by Galapagos NV, H1 2014 210
Inflammation - Pipeline by Synta Pharmaceuticals Corp., H1 2014 211
Inflammation - Pipeline by BioAlliance Pharma SA, H1 2014 212
Inflammation - Pipeline by Innate Pharma SA, H1 2014 213
Inflammation - Pipeline by MetrioPharm AG, H1 2014 214
Inflammation - Pipeline by Proteo, Inc., H1 2014 215
Inflammation - Pipeline by Verona Pharma Plc, H1 2014 216
Inflammation - Pipeline by Angelini Group, H1 2014 217
Inflammation - Pipeline by Affitech A/S, H1 2014 218
Inflammation - Pipeline by Debiopharm International S.A., H1 2014 219
Inflammation - Pipeline by Chroma Therapeutics Ltd., H1 2014 220
Inflammation - Pipeline by Advinus Therapeutics Ltd., H1 2014 221
Inflammation - Pipeline by CJ CheilJedang Corp., H1 2014 222
Inflammation - Pipeline by Antitope Ltd., H1 2014 223
Inflammation - Pipeline by Axxam SpA, H1 2014 224
Inflammation - Pipeline by INSYS Therapeutics, Inc., H1 2014 225
Inflammation - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 226
Inflammation - Pipeline by Alba Therapeutics Corporation, H1 2014 227
Inflammation - Pipeline by AcurePharma AB, H1 2014 228
Inflammation - Pipeline by Ambit Biosciences Corporation, H1 2014 229
Inflammation - Pipeline by Viron Therapeutics, Inc., H1 2014 230
Inflammation - Pipeline by Immupharma Plc, H1 2014 231
Inflammation - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 232
Inflammation - Pipeline by Molecular Partners AG, H1 2014 233
Inflammation - Pipeline by Physica Pharma, H1 2014 234
Inflammation - Pipeline by Acceleron Pharma, Inc., H1 2014 235
Inflammation - Pipeline by Lipicard Technologies Limited, H1 2014 236
Inflammation - Pipeline by Conaris Research Institute AG, H1 2014 237
Inflammation - Pipeline by Hutchison MediPharma Limited, H1 2014 238
Inflammation - Pipeline by Affibody AB, H1 2014 239
Inflammation - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 240
Inflammation - Pipeline by Aquinox Pharmaceuticals Inc., H1 2014 241
Inflammation - Pipeline by Argos Therapeutics, Inc., H1 2014 242
Inflammation - Pipeline by Aegera Therapeutics Inc., H1 2014 243
Inflammation - Pipeline by Anchor Therapeutics, Inc., H1 2014 244
Inflammation - Pipeline by AnaptysBio, Inc., H1 2014 245
Inflammation - Pipeline by Allozyne, Inc., H1 2014 246
Inflammation - Pipeline by Funxional Therapeutics Ltd, H1 2014 247

List of Figures
Number of Products under Development for Inflammation, H1 2014 72
Number of Products under Development for Inflammation - Comparative Analysis, H1 2014 73
Number of Products under Development by Companies, H1 2014 74
Number of Products under Investigation by Universities/Institutes, H1 2014 94
Comparative Analysis by Clinical Stage Development, H1 2014 101
Comparative Analysis by Early Stage Products, H1 2014 102
Assessment by Monotherapy Products, H1 2014 363
Assessment by Combination Products, H1 2014 364
Number of Products by Top 10 Target, H1 2014 365
Number of Products by Stage and Top 10 Target, H1 2014 366
Number of Products by Top 10 Mechanism of Action, H1 2014 375
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 376
Number of Products by Top 10 Route of Administration, H1 2014 386
Number of Products by Stage and Top 10 Route of Administration, H1 2014 387
Number of Products by Top 10 Molecule Type, H1 2014 389
Number of Products by Stage and Top 10 Molecule Type, H1 2014 390

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.